Advertisement
Advertisement
RLAY
Relay Therapeutics, Inc. Common Stock
13.66
USDSponsored
+0.64
+4.92%
May 21, 16:00 UTC -4
Closed
After-Market
14.04
+0.38
+2.75%
RLAY Earnings Reports
Positive Surprise Ratio
RLAY beat 14 of 24 last estimates.
58%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$238.00K
/-$0.40
Implied change from Q1 26 (Revenue/ EPS)
-92.07%
/-2.44%
Implied change from Q2 25 (Revenue/ EPS)
-64.85%
/-2.44%
Relay Therapeutics, Inc. Common Stock earnings per share and revenue
On May 05, 2026, RLAY reported earnings of -0.41 USD per share (EPS) for Q1 26, missing the estimate of -0.38 USD, resulting in a -6.66% surprise. Revenue reached 3.00 million, compared to an expected 2.61 million, with a 14.89% difference. The market reacted with a -0.62% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 238.00 thousand USD, implying an decrease of -2.44% EPS, and decrease of -92.07% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Relay Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Relay Therapeutics, Inc. Common Stock reported EPS of -$0.41, missing estimates by -6.66%, and revenue of $3.00M, 14.89% above expectations.
How did the market react to Relay Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.62%, changed from $13.00 before the earnings release to $12.92 the day after.
When is Relay Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Relay Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Relay Therapeutics, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $238.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement